Company optimally positioned to increase market share in highly valued Australian hemostat market, following positive feedback from physician usage of HEMOBLAST™ Bellows

Building on inclusion on the Australian Register of Therapeutic Goods (ARTG) and agreed partnership with LHC in 2019

SAINT-PRIEST, France and NEW YORK, Oct. 8, 2020 /PRNewswire...